Skip to main content

CORRECTION article

Front. Oncol., 26 July 2022
Sec. Thoracic Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.972329

Corrigendum: identification and validation of lncRNA-SNHG17 in lung adenocarcinoma: a novel prognostic and diagnostic indicator

This article is a correction to:

  1. Identification and Validation of lncRNA-SNHG17 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic Indicator

    1. Read original article
Xinyan Li&#x;Xinyan Li1†Yixiao Yuan&#x;Yixiao Yuan2†Mintu Pal*Mintu Pal3*Xiulin Jiang,*Xiulin Jiang4,5*
  • 1Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 2Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
  • 3Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Bathinda, Punjab, India
  • 4Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, China
  • 5Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing, China

A Corrigendum on
Identification and Validation of lncRNA-SNHG17 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic Indicator

by Li X, Yuan Y, Pal M and Jiang X (2022)  12:929655. doi: 10.3389/fonc.2022.929655

In the original article, author Mintu Pal was mistakenly affiliated with - “Biotechnology Division, North East Institute of Science and Technology, Jorhat, India” as published. The correct affiliation should be – “Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Bathinda, Punjab, India” as above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: lung adenocarcinoma, inflammatory response-related gene, DNA methylation, ceRNA, immune cell infiltration, drug sensitivity

Citation: Li X, Yuan Y, Pal M and Jiang X (2022) Corrigendum: identification and validation of lncRNA-SNHG17 in lung adenocarcinoma: a novel prognostic and diagnostic indicator. Front. Oncol. 12:972329. doi: 10.3389/fonc.2022.972329

Received: 18 June 2022; Accepted: 01 July 2022;
Published: 26 July 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Li, Yuan, Pal and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xiulin Jiang, amlhbmd4aXVsaW5AbWFpbC5raXouYWMuY24=; Mintu Pal, bXBhbDI0QHlhaG9vLmNvbQ==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.